BRIEF — KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study

Oct 15 (Reuters) — Kdventures AB: Portfolio Company Modus Therapeutics Temporarily Pauses Enrollment In Phase 2a Study Of Sevuparin In Chronic Kidney Disease With Anemia Pause Is Not Result Of A Regulatory Decision Pause Follows Reporting Of Susar After Serious Adverse Event In Sevuparin Study Proof-of-concept Readout For Sevuparin Study Expected In Q1 2027 No Ongoing Treatment Discontinued In Sevuparin Study At Time Of Pause Source text:... Further company coverage: KDV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)